Does Metronidazole Cause Cancer in Humans?

Metronidazole is classified by the International Agency for Research on Cancer (IARC) as a Group 2B substance, meaning “possibly carcinogenic to humans,” but that label rests almost entirely on animal experiments and bacterial DNA studies rather than on convincing human evidence. Multiple large epidemiological studies spanning decades have failed to find a clear, consistent link between standard metronidazole use and cancer in people. The story is more nuanced than a simple yes or no, though, because a few specific cancer types keep surfacing in the data with faint signals that researchers have not been able to dismiss entirely.

The Animal Evidence That Started the Debate

Concern about metronidazole and cancer traces back to rodent experiments in the 1970s and 1980s. When mice were given prolonged high doses of the drug, three separate studies found an increased incidence of lung tumors, and one study noted a possible rise in lymphatic cancers in female mice. Rats given the drug appeared to develop more liver tumors. On the surface, those findings sound alarming, but the details matter. A toxicological review noted that the mouse lung-tumor effect was probably nonspecific: simply varying the amount of standard food mice ate produced similar shifts in tumor rates. The rat liver-tumor finding, meanwhile, was undermined by the original researchers’ failure to account for the fact that metronidazole significantly improved the rats’ survival, meaning drug-treated animals simply lived long enough to develop more age-related tumors. Two carcinogenicity studies in hamsters came back entirely negative.¹

A later experiment in rats that had colon cancer chemically induced found that long-term metronidazole modestly increased the number of colon tumors per animal, but the increase was statistically significant only in a subgroup that also underwent surgery. The drug alone did not produce a clear carcinogenic signal even under conditions designed to maximize the chance of finding one.²

How Metronidazole Interacts with DNA

Metronidazole belongs to the nitroimidazole class of drugs. Its therapeutic power and its theoretical cancer risk come from the same basic property: when the nitro group on the molecule gets chemically reduced inside a cell, the resulting products can break DNA strands. This is exactly how it kills bacteria and parasites. In organisms that use oxygen-free metabolic pathways, the drug gets activated readily, and the activated form damages the microbe’s DNA enough to be lethal.³

In laboratory bacteria, this process is measurably mutagenic. Metronidazole at growth-inhibiting concentrations stimulates specific types of DNA mutations in Helicobacter pylori and in E. coli engineered to carry the same drug-activating gene. At higher concentrations, it directly fragments bacterial DNA.⁴ The question has always been whether these effects extend to human cells under real-world conditions, and that turns out to be a much harder thing to demonstrate.

Why Rodent Results Do Not Translate Neatly to Humans

One underappreciated issue in this debate is that different species metabolize metronidazole differently. A study comparing drug metabolism in isolated liver cells from mice and rats found quantitative differences in how quickly each species processed metronidazole into its various breakdown products, and the researchers concluded that neither species provided an ideal model for human metabolism of the drug.⁵ The pathways were qualitatively similar but differed in speed and efficiency, which matters because the rate of drug activation and clearance determines how long DNA-damaging intermediates linger in cells.

Human cells also lack the ferredoxin-linked reduction systems that make bacteria and parasites so vulnerable to metronidazole. The selective toxicity of the drug depends on this difference: it gets activated efficiently inside microbes but far less efficiently inside mammalian cells. That is why the drug kills infections without destroying the patient’s own tissue. It also means that extrapolating from bacterial mutagenicity experiments to human cancer risk requires a large logical leap, one that decades of human data have not validated.

What Decades of Human Follow-Up Data Show

The most direct way to test whether a drug causes cancer in people is to follow large groups of users over many years and compare their cancer rates to what would be expected in the general population or to matched nonusers. Several studies have done exactly this with metronidazole, and the overall picture is reassuring.

A study published in Mayo Clinic Proceedings tracked women treated with metronidazole for vaginal trichomoniasis and calculated standardized morbidity ratios for cancer across three different population registries. The ratios were modestly elevated at 1.2, 1.4, and 1.5 depending on the reference population, but the standardized mortality ratio for cancer at all sites was 1.4 with a confidence interval that included 1.0, meaning the increase was not statistically significant. The authors concluded that the data suggested no significant increase in cancer-related illness or death among exposed women.⁶

A larger matched study followed metronidazole users and nonusers over an extended period and found that after the first seven years, cancer incidence was nearly identical between the two groups: roughly 652 per 100,000 person-years among users versus 662 among nonusers. The relative risk was 0.98 with a confidence interval of 0.80 to 1.20. Stratifying by age and gender did not reveal any hidden association.⁷

One early study that did find a concerning signal was published in the New England Journal of Medicine. Researchers observed four cases of lung cancer among metronidazole users when only about 0.6 cases would have been expected. That sounds dramatic until you learn that all four women who developed lung cancer were smokers, making the finding a textbook example of confounding rather than a drug effect.⁸

Specific Cancer Types Under Scrutiny

While overall cancer rates have not risen consistently in metronidazole users, researchers have looked at individual cancer types more closely, and a few warrant mention.

Breast Cancer

A study of about 2.1 million women in Denmark found no statistically significant increase in breast cancer risk associated with more than 100 days of metronidazole use. The hazard ratio was no greater than 1.03.⁹ A later meta-analysis looking at antibiotics and breast cancer across multiple studies found a marginal association for nitroimidazole and metronidazole use, with a pooled relative risk of 1.05 and a confidence interval that barely touched 1.00 on the lower end. That is a small enough effect that it could easily be explained by residual confounding or chance.¹⁰ It is worth noting that penicillins and tetracyclines showed similar or larger associations in that same meta-analysis, suggesting that the link between antibiotic use broadly and breast cancer may reflect something about the conditions requiring treatment, or about microbiome disruption, rather than about metronidazole specifically.

Colorectal Cancer

An updated meta-analysis of antibiotics and colorectal neoplasia found that anti-anaerobic antibiotics, including metronidazole, were associated with increased risk of colorectal cancer. This signal was stronger than for many other antibiotic classes.¹¹ The catch is that this finding comes with a plausible alternative explanation: antibiotics that kill anaerobic gut bacteria could shift the balance of intestinal flora in ways that promote or permit colorectal tumors. That would make the cancer risk a consequence of microbiome disruption, not a direct mutagenic effect of metronidazole on colon cells. The distinction matters because the same mechanism would apply to any drug that disrupts gut anaerobes, and because addressing the microbiome effect (through, say, probiotics or dietary strategies) would be a very different intervention than withdrawing the drug itself.

Other Cancer Types

A review of retrospective studies found that metronidazole had been flagged as a potential risk factor for lung cancer, cervical cancer, breast cancer, cholangiocarcinoma, and neuroblastoma across various small data sets. The review emphasized, however, that while animal carcinogenicity had been confirmed, the evidence in humans remained controversial.¹² The study sizes were often very small, and none of the findings had been replicated convincingly enough to establish a causal relationship.

Prenatal Exposure and Childhood Cancer

Pregnant women sometimes need metronidazole for bacterial vaginosis or other infections, and the question of whether in-utero exposure could increase the child’s cancer risk is understandably worrying. A study using a large cohort of children exposed to metronidazole before birth found no significant increase in the adjusted relative risk for all childhood cancers combined. The relative risk for all cancers was 0.81, with a confidence interval well spanning 1.0, meaning the point estimate actually leaned toward a lower risk, though not significantly so. The study also looked at specific childhood cancers. There were no cases of leukemia among exposed children, and while the relative risk for neuroblastoma was somewhat elevated at 2.60, the confidence interval was wide enough (0.89 to 7.59) that the finding was not statistically significant.¹³ The neuroblastoma signal has shown up in other small data sets, but no large confirmatory study has established a true link.

The Antibiotic Paradox and Gut Bacteria

Ironically, some of the most recent research suggests that metronidazole might in certain contexts work against colorectal cancer rather than promote it. A mouse study examined whether metronidazole could reduce the harmful effects of Fusobacterium nucleatum, a gut bacterium strongly linked to colorectal cancer development and progression. The researchers found that metronidazole suppressed tumor occurrence and growth, reduced liver metastases, and altered the intestinal bacterial community in ways that appeared beneficial.¹⁴

This sits in interesting tension with the meta-analysis evidence linking anti-anaerobic antibiotic use to higher colorectal cancer rates in human populations.¹¹ One way to reconcile the two findings is that the effect likely depends on which bacteria dominate a person’s gut at the time of treatment. Killing off Fusobacterium nucleatum might be protective, while broadly depleting beneficial anaerobes might be harmful. The net effect of metronidazole on colorectal cancer risk in any individual would then depend on the specific composition of their microbiome, the duration of use, and factors researchers have barely begun to untangle.

Why Confounding Keeps Clouding the Picture

A recurring problem in metronidazole-cancer research is that the people who take metronidazole are not a random sample of the population. Metronidazole is commonly prescribed for conditions like bacterial vaginosis, trichomoniasis, Clostridioides difficile infection, and various anaerobic infections. Some of these conditions are associated with lifestyle factors that independently affect cancer risk. The NEJM study where all four excess lung-cancer cases were smokers illustrates this perfectly.⁸ Smoking, alcohol use, sexual behavior, and chronic inflammation can all co-occur with the conditions metronidazole treats, creating confounders that are difficult to fully adjust for in observational studies.

There is also a more subtle form of confounding called “confounding by indication,” in which the underlying infection itself, rather than the drug used to treat it, is what correlates with later cancer. Chronic infections and the inflammation they cause are established contributors to cancer development. Disentangling the drug’s effect from the disease’s effect would require a randomized trial in which some people with infections are denied treatment, which is obviously unethical. Researchers are left relying on clever statistical adjustments and large matched cohorts, which can minimize but never fully eliminate this issue.

How the Regulatory World Views the Risk

IARC’s Group 2B classification for metronidazole means the agency considers the evidence of carcinogenicity “sufficient” in animals but “inadequate” in humans. Group 2B is a large category that includes things like aloe vera extract, pickled vegetables, and gasoline engine exhaust, reflecting theoretical concern rather than demonstrated human harm. Regulatory agencies have not pulled metronidazole from the market or restricted its use on cancer grounds. The drug remains on the World Health Organization’s List of Essential Medicines, recognized as one of the most effective and broadly needed medications in global health.

A 2025 review of antibiotic-induced genotoxicity across multiple drug classes noted that most positive signals come from preclinical laboratory models, and that clinically validated long-term outcomes in humans, particularly for cancer endpoints, remain inconsistently demonstrated for most antibiotic classes. The review singled out metronidazole as having the most data on this topic, but even for metronidazole, the human evidence has not reached the level that would change prescribing recommendations.¹⁵

Topical Versus Oral Use

Many people encounter metronidazole not as a pill swallowed for an infection but as a topical gel or cream applied to the skin for rosacea. The pharmacokinetics of topical application are fundamentally different from oral dosing. When applied to the skin, only a small fraction of the drug reaches the bloodstream, resulting in systemic levels that are a tiny fraction of what oral therapy produces. For the same reason that a short course of oral metronidazole has not been linked to cancer, the much lower systemic exposure from topical use is even less likely to pose a meaningful risk. People using metronidazole gel for rosacea are in a very different exposure category from patients taking weeks of oral metronidazole for, say, a severe C. difficile infection or Crohn’s-related complications.

What This Means for People Prescribed Metronidazole

If your doctor prescribes metronidazole for an infection, the current weight of evidence strongly favors taking it. The drug is highly effective against the pathogens it targets, and untreated anaerobic infections carry their own serious risks, including sepsis and tissue destruction. The cancer concern, while scientifically interesting, has not materialized into a detectable real-world increase in cancer rates after more than four decades of epidemiological study in large populations.⁷

The situation gets genuinely more complex for people who need metronidazole continuously for months or years, as sometimes happens with Crohn’s disease or certain chronic conditions. Most of the reassuring human data come from populations that used the drug in relatively short courses. Whether truly chronic use at therapeutic doses carries a different risk profile is less studied and harder to know. In these cases, the decision involves weighing a measurable benefit (controlling a disease that can be debilitating) against a theoretical risk that five decades of study have not confirmed. That calculus overwhelmingly favors treatment, but it is reasonable to discuss with your physician and to ensure no equally effective alternative exists if the concern weighs on you.